Teva Pharmaceutical Industries (NYSE:TEVA) Issues Quarterly Earnings Results

Teva Pharmaceutical Industries (NYSE:TEVA) posted its quarterly earnings results on Wednesday. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01, Zacks reports. Teva Pharmaceutical Industries had a positive return on equity of 42.92% and a negative net margin of 5.73%. Teva Pharmaceutical Industries updated its FY 2025 guidance to 2.350-2.650 EPS.

Teva Pharmaceutical Industries Stock Down 1.0 %

Shares of TEVA stock opened at $21.57 on Wednesday. Teva Pharmaceutical Industries has a twelve month low of $11.48 and a twelve month high of $22.80. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The stock’s 50 day simple moving average is $19.94 and its 200 day simple moving average is $18.47. The company has a market capitalization of $24.43 billion, a price-to-earnings ratio of -25.37, a PEG ratio of 1.11 and a beta of 0.73.

Analyst Upgrades and Downgrades

TEVA has been the subject of a number of recent analyst reports. Piper Sandler increased their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $28.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. JPMorgan Chase & Co. raised their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. Finally, StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $22.63.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is owned by corporate insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.